Skip to main content

Advertisement

SpringerLink
Log in

Effect of L-arginine supplementation on NO production in man

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

L-arginine is the substrate for the enzyme nitric oxide synthase (NOS), which is responsible for the production of nitric oxide (NO), an endogenous messenger molecule involved in many of the processes associated with the development of atherosclerosis. Acute and chronic administration of L-arginine has been shown to improve endothelial function in animal models of hypercholesterolemia and atherosclerosis. Therefore, numerous studies have been conducted to elucidate whether dietary L-arginine supplementation can augment NO production in humans and thereby improve vascular health. In this review, the results of studies of intravenous and oral L-arginine supplementation with a wide spectrum of doses, study duration, and surrogate parameters of endothelial function are summarized. The pharmacokinetics of L-arginine have been investigated; side effects are rare and mostly mild and dose-dependent. Several possible mechanisms of action of L-arginine are discussed. An evaluation of L-arginine as a therapeutic agent from the point of view of a clinical pharmacologist is given.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Abdelhamed AI, Reis SE, Sane DC, Brosnihan KB, Preli RB, Herrington DM (2003) No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J 145:E15

    Article  PubMed  CAS  Google Scholar 

  2. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS (1995) Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 26:1054–1061

    Article  PubMed  CAS  Google Scholar 

  3. Adams MR, Jessup W, Celermajer DS (1997) Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 29:491–497

    Article  PubMed  CAS  Google Scholar 

  4. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS (1997) Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 129:261–269

    Article  PubMed  CAS  Google Scholar 

  5. Blum A, Cannon RO III, Costello R, Schenke WH, Csako G (2000) Endocrine and lipid effects of oral L-arginine treatment in healthy postmenopausal women. J Lab Clin Med 135:231–237

    Article  PubMed  CAS  Google Scholar 

  6. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO III (2000) Oral L-arginine in patients with coronary artery disease on medical management. Circulation 101:2160–2164

    PubMed  CAS  Google Scholar 

  7. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO III(2000) Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women. J Am Coll Cardiol 35:271–276

    Article  PubMed  CAS  Google Scholar 

  8. Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K, Frölich JC (1994) L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 87:303–310

    PubMed  Google Scholar 

  9. Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, Alexander K, Frölich JC (1996) L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 93:85–90

    PubMed  Google Scholar 

  10. Bode-Böger SM, Böger RH, Galland A, Tsikas D, Frölich JC (1998) L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 46:489–497

    Article  PubMed  Google Scholar 

  11. Bode-Böger SM, Böger RH, Löffler M, Tsikas D, Brabant G, Frölich JC (1999) L-arginine stimulates NO-dependent vasodilation in healthy humans—effect of somatostatin pretreatment. J Investig Med 47:43–50

    PubMed  Google Scholar 

  12. Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC (2003) Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 8:77–81

    Article  PubMed  Google Scholar 

  13. Böger RH, Mugge A, Bode-Böger SM, Heinzel D, Hoper MM, Frölich JC (1996) Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 34:323–328

    PubMed  Google Scholar 

  14. Böger RH, Bode-Böger SM, Brandes RP, Phivthong-Ngam L, Böhme M, Nafe R, Mugge A, Frölich JC (1997) Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 96:1282–1290

    PubMed  Google Scholar 

  15. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842–1847

    PubMed  Google Scholar 

  16. Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC (1998) Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32:1336–1344

    Article  PubMed  Google Scholar 

  17. Böger RH, Bode-Böger SM (2001) The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 41:79–99

    Article  PubMed  Google Scholar 

  18. Boyd JR, Olin BR (1984) Drug facts and comparisons. Lippincott, St. Louis

  19. Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682–685

    Article  PubMed  CAS  Google Scholar 

  20. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, Ignarro LJ (1996) Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 271:H1988–1998

    PubMed  CAS  Google Scholar 

  21. Campisi R, Czernin J, Schoder H, Sayre JW, Schelbert HR (1999) L-arginine normalizes coronary vasomotion in long-term smokers. Circulation 99:491–497

    PubMed  CAS  Google Scholar 

  22. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K (1997) Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 80:331–333

    Article  PubMed  CAS  Google Scholar 

  23. Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP (2000) Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20:1040–1046

    PubMed  CAS  Google Scholar 

  24. Chauhan A, More RS, Mullins PA, Taylor G, Petch C, Schofield PM (1996) Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol 28:1796–1804

    Article  PubMed  CAS  Google Scholar 

  25. Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL (1996) Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 27:1207–1213

    Article  PubMed  CAS  Google Scholar 

  26. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE (1996) Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 97:1989–1994

    Article  PubMed  CAS  Google Scholar 

  27. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME (1992) Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 90:1168–1172

    Article  PubMed  CAS  Google Scholar 

  28. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 90:1248–1253

    Article  PubMed  CAS  Google Scholar 

  29. Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, MacAllister RJ (2001) Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 60:2318–2323

    Article  PubMed  CAS  Google Scholar 

  30. Delles C, Schneider MP, Oehmer S, Fleischmann EH, Schmieder RE (2003) L-arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. Diabetes Care 26:1836–1840

    Article  PubMed  CAS  Google Scholar 

  31. Drexler H, Zeiher AM, Meinzer K, Just H (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338:1546–1550

    Article  PubMed  CAS  Google Scholar 

  32. Esposito K, Nappo F, Giugliano F, Giugliano G, Marfella R, Giugliano D (2003) Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. Am J Clin Nutr 77:139–143

    PubMed  CAS  Google Scholar 

  33. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373–376

    Article  PubMed  CAS  Google Scholar 

  34. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ (1995) Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 316:247–249

    Google Scholar 

  35. Giraldelo CM, Zappellini A, Muscara MN, De Luca IM, Hyslop S, Cirino G, Zatz R, De Nucci G, Antunes E (1994) Effect of arginine analogues on rat hind paw oedema and mast cell activation in vitro. Eur J Pharmacol 257:87–93

    Article  PubMed  CAS  Google Scholar 

  36. Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA (1999) Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 99:3234–3240

    PubMed  CAS  Google Scholar 

  37. Gold ME, Bush PA, Ignarro LJ (1989) Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 164:714–721

    Article  PubMed  CAS  Google Scholar 

  38. Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N, Schuler G (2000) Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 35:706–713

    Article  PubMed  CAS  Google Scholar 

  39. Hand MF, Haynes WG, Webb DJ (1998) Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 53:1068–1077

    Article  PubMed  CAS  Google Scholar 

  40. Hedin SG (1895) Über die Bildung von Arginin aus Proteinkörper. Z Physiol Chem 21:155–168

    CAS  Google Scholar 

  41. Higashi Y, Oshima T, Ozono R, Matsuura H, Kambe M, Kajiyama G (1999) Effect of L-arginine infusion on systemic and renal hemodynamics in hypertensive patients. Am J Hypertens 12:8–15

    Article  PubMed  CAS  Google Scholar 

  42. Huynh NT, Tayek JA (2002) Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 21:422–427

    PubMed  CAS  Google Scholar 

  43. Jay MT, Chirico S, Siow RC, Bruckdorfer KR, Jacobs M, Leake DS, Pearson JD, Mann GE (1997) Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Exp Physiol 82:349–360

    PubMed  CAS  Google Scholar 

  44. Kastrup EK, Olin BR (1987) Drug facts and comparisons. Lippincott, St. Louis, pp 310–311

  45. Kikuta K, Sawamura T, Miwa S, Hashimoto N, Masaki T (1998) High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res 83:1088–1096

    PubMed  CAS  Google Scholar 

  46. Lass A, Suessenbacher A, Wolkart G, Mayer B, Brunner F (2002) Functional and analytical evidence for scavenging of oxygen radicals by L-arginine. Mol Pharmacol 61:1081–1088

    Article  PubMed  CAS  Google Scholar 

  47. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, Dagre AG, Stamatelopoulos K, Protogerou A, Stamatelopoulos SF (2002) Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 86:317–323

    Article  PubMed  Google Scholar 

  48. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr (1998) Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97:2123–2128

    PubMed  CAS  Google Scholar 

  49. Maxwell AJ, Anderson BE, Cooke JP (2000) Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 5:11–19

    PubMed  CAS  Google Scholar 

  50. Maxwell AJ, Anderson BE, Zapien MP, Cooke JP (2000) Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc Drugs Ther 14:309–316

    Article  PubMed  CAS  Google Scholar 

  51. McDonald KK, Zharikov S, Block ER, Kilberg MS (1997) A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 272:31213–31216

    Article  PubMed  CAS  Google Scholar 

  52. Mehta S, Stewart DJ, Langleben D, Levy RD (1995) Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 92:1539–1545

    PubMed  CAS  Google Scholar 

  53. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141–1146

    PubMed  CAS  Google Scholar 

  54. Mudge GH (1980) Agents affecting volume and composition of body fluids. In: Goodman LS, Gilman AG (eds) The pharmacologic basis of therapeutics, 6th edn. Macmillan, New York, pp 892–915

  55. Nakaki T, Hishikawa K, Suzuki H, Saruta T, Kato R (1990) L-arginine-induced hypotension. Lancet 336:696

    Article  PubMed  CAS  Google Scholar 

  56. Oomen CM, van Erk MJ, Feskens EJ, Kok FJ, Kromhout D (2000) Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 20:2134–2139

    PubMed  CAS  Google Scholar 

  57. Orchard CH, Cingolani HE (1994) Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 28:1312–1319

    Article  PubMed  CAS  Google Scholar 

  58. Otsuji S, Nakajima O, Waku S, Kojima S, Hosokawa H, Kinoshita I, Okubo T, Tamoto S, Takada K, Ishihara T (1995) Attenuation of acetylcholine-induced vasoconstriction by L-arginine is related to the progression of atherosclerosis. Am Heart J 129:1094–1100

    Article  PubMed  CAS  Google Scholar 

  59. Panza JA, Casino PR, Badar DM, Quyyumi AA (1993) Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 87:1475–1481

    PubMed  CAS  Google Scholar 

  60. Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F, Galli-Kienle M, Pozza G, Alberti KG (2001) Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 24:875–880

    Article  PubMed  CAS  Google Scholar 

  61. Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, Paroni R, Galluccio E, Pozza G, Chierchia S, Margonato A (2003) Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 107:429–436

    Article  PubMed  CAS  Google Scholar 

  62. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH (1996) Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 93:2135–2141

    PubMed  CAS  Google Scholar 

  63. Schellong SM, Böger RH, Burchert W, Bode-Böger SM, Galland A, Frölich JC, Hundeshagen H, Alexander K (1997) Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H2 15O positron emission tomography study. Clin Sci 93:159–165

    PubMed  CAS  Google Scholar 

  64. Schulze E, Steiger E (1886) Über das Arginin. Z Physiol Chem 11:43–46

    Google Scholar 

  65. Sorensen SPL (1910) Über die Synthese des dl-Arginins (α-amino-δ-guanidino-n-Valeriansäure) und der Isomeren (δ-guanidino-α-amino-n-Valeriansäure). Chem Ber 43:643–651

    Article  CAS  Google Scholar 

  66. Suschek CV, Schnorr O, Hemmrich K, Aust O, Klotz LO, Sies H, Kolb-Bachofen V (2003) Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation 107:2607–2614

    PubMed  CAS  Google Scholar 

  67. Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, Frölich JC, Böger RH (2003) ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57:244–252

    Article  PubMed  CAS  Google Scholar 

  68. Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, Tsao PS, Cooke JP (1997) Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 17:3557–3564

    PubMed  CAS  Google Scholar 

  69. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE (1998) Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 32:110–116

    Article  PubMed  CAS  Google Scholar 

  70. Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P (1997) Coronary stenosis dilatation induced by L-arginine. Lancet 349:1812–1813

    Article  PubMed  CAS  Google Scholar 

  71. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128

    Article  PubMed  CAS  Google Scholar 

  72. Wallner S, Hermetter A, Mayer B, Wascher TC (2001) The alpha-amino group of L-arginine mediates its antioxidant effect. Eur J Clin Invest 31:98–102

    Article  PubMed  CAS  Google Scholar 

  73. Wei LH, Jacobs AT, Morris SM Jr, Ignarro LJ (2000) IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 279:C248–256

    PubMed  CAS  Google Scholar 

  74. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, Tsao PS, Cooke JP (1997) Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 29:479–485

    Article  PubMed  CAS  Google Scholar 

  75. Yamamoto A, Hoshi K, Ichihara K (1998) Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 361:143–149

    Article  PubMed  CAS  Google Scholar 

  76. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2127–2128

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, University Hospital Otto-von-Guericke-University, Leipziger Str. 44, 39120, Magdeburg, Germany

    Stefanie M. Bode-Böger

Authors
  1. Stefanie M. Bode-Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie M. Bode-Böger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bode-Böger, S.M. Effect of L-arginine supplementation on NO production in man. Eur J Clin Pharmacol 62 (Suppl 1), 91–99 (2006). https://doi.org/10.1007/s00228-005-0004-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0004-z

Keywords

Search

Navigation